Publications by authors named "M Lopez-Yurda"
Background: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, response-directed treatment strategies.
Methods: The OpACIN-neo and PRADO trials were phase 2 studies evaluating neoadjuvant treatment with ipilimumab and nivolumab in stage III melanoma.
Introduction: DW-MRI is a non-invasive way to determine the peritoneal cancer index (PCI) in colorectal cancer (CRC) patients with peritoneal metastases (PM). However, like surgeons during surgery, radiologists struggle to differentiate between PM and fibrosis. This study aimed to investigate the agreement between the PCI as determined by MRI (mriPCI), during surgery (sPCI) and histopathology examination (pPCI) in CRC patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibition (ICI) combined with chemotherapy is the standard treatment for stage II-III triple-negative breast cancer, but the effectiveness of ICI alone remains unclear.
- The adaptive BELLINI trial found that short-term ICI treatments led to immune activation in a significant portion of patients, correlating immune response with tumor-infiltrating lymphocytes.
- A new cohort is being studied with patients who have high levels of these lymphocytes; early results show a notable rate of major and complete pathological responses post-treatment, suggesting that neoadjuvant ICI could be a promising approach without chemotherapy.
Background: Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC) and diffuse (dif-GC) gastric cancer.
Methods: Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts.
Article Synopsis
- Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in Stage III ovarian cancer after surgery, but optimizing patient selection is crucial to enhance treatment effectiveness and reduce unnecessary interventions.
- A study analyzed RNA sequencing data from 147 patients with high-grade serous ovarian cancer to identify biomarkers for HIPEC benefit, focusing on gene expression and tumor cell composition.
- The results suggested that the absence of macrophages and the presence of B cells in the tumor environment could predict HIPEC effectiveness, a finding supported by histological validation, indicating a need for further research on immune cell composition's role in treatment response.